142 filings
Page 5 of 8
8-K
i8vnbxpcpxjvjb50p0
1 Aug 18
Mirati Therapeutics Reports Second Quarter
4:25pm
8-K
k37uyq7
7 Jun 18
Mirati Therapeutics Announces Proposed Public Offering of Common Stock
4:03pm
8-K
939t9la6p192rt9
18 May 18
Submission of Matters to a Vote of Security Holders
4:26pm
8-K
s5au9p
7 May 18
Mirati Therapeutics Reports First Quarter
4:31pm
8-K
f9mj3q4ehjniv rwoyf
24 Apr 18
Mirati Therapeutics Announces Progress of Lead Programs
12:00am
8-K
rnt6gkb
10 Apr 18
Entry into a Material Definitive Agreement
12:00am
8-K
y2xfp6rvni
8 Mar 18
Mirati Therapeutics Reports Fourth Quarter and Full-year 2017 Financial Results
12:00am
8-K
v0v95
24 Jan 18
Departure of Directors or Certain Officers
12:00am
8-K
zsyu181
11 Jan 18
BeiGene and Mirati Therapeutics Announce Exclusive License Agreement for Sitravatinib in the Asia Pacific Region
12:00am
8-K
a5i6jwc3ql7vx2qwzpa
16 Nov 17
Mirati Therapeutics Announces Proposed Public Offering of Common Stock
12:00am
8-K
5cqm6yriqd g1zj
13 Nov 17
Mirati Therapeutics Announces Advancement of First-in-class Opportunities with Sitravatinib and Kras Inhibitor Programs
12:00am
8-K
3bp1z0fb29xpr65lm
1 Nov 17
Mirati Therapeutics Reports Third Quarter 2017
12:00am
8-K
gvz rzk22i1e3
14 Sep 17
Mirati Therapeutics Presents Positive Preliminary
12:00am
8-K
7r5 pvnn5
3 Aug 17
Mirati Therapeutics Reports Second Quarter 2017
12:00am
8-K
hz1hsmtes
27 Jun 17
Mirati Therapeutics Announces Appointment of
12:00am
8-K
ay6jhr85lbr
19 May 17
Departure of Directors or Certain Officers
12:00am
8-K
59hm5r9bh yqonchr
4 May 17
Mirati Therapeutics Reports First Quarter 2017
12:00am
8-K
0367eqev bkcd7
27 Mar 17
Entry into a Material Definitive Agreement
12:00am
8-K
f0yzd8kdj4ai9 ngox
9 Mar 17
Mirati Therapeutics Reports Financial Results and Provides Business
12:00am
8-K
op2pl6ygmkeky2pu1
1 Feb 17
Departure of Directors or Certain Officers
12:00am